Athira Pharma Inc
ATHA0.378USD
+0.008+2.11%
交易中 （美東）報價延遲15分鐘
14.76M總市值
虧損本益比TTM
關於 Athira Pharma Inc 公司
Athira Pharma, Inc. 是一家處於臨牀後期的生物製藥公司。該公司專注於開發用於恢復神經元健康和減緩神經退化的小分子。該公司的產品線包括用於中樞神經系統 (CNS)、周圍神經系統和其他適應症的血腦屏障可滲透和外周受限的候選藥物。其主要候選藥物 fosgonimeton (ATH-1017) 是一種皮下給藥的小分子正向調節劑，可調節肝細胞生長因子/間充質上皮轉化因子 (HGF/MET) 系統，用於治療中樞神經系統疾病。該公司還在評估其他候選藥物，以用於治療神經性疼痛、肌萎縮側索硬化症、帕金森病和其他神經退行性疾病。該公司的 ATH-1020 已在健康志願者中完成了 I 期單次遞增劑量評估。該公司的 ATH-1105 是一種小分子化合物，旨在作爲口服、每日一次的治療方法，以增強 HGF/MET 系統。
公司簡介
公司代碼ATHA
公司名稱Athira Pharma Inc
上市日期Sep 18, 2020
CEODr. Mark James Litton, Ph.D.
員工數量26
證券類型Ordinary Share
年結日Sep 18
公司地址18706 North Creek Parkway, Suite 104
城市BOTHELL
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編98011
電話14256208501
網址https://www.athira.com/
公司代碼ATHA
上市日期Sep 18, 2020
CEODr. Mark James Litton, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
345.49K
-6.78%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
168.90K
-4.81%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
111.88K
-7.08%
Mr. Robert Renninger
Mr. Robert Renninger
Senior Vice President - Finance, Accounting
Senior Vice President - Finance, Accounting
109.19K
-2.58%
Ms. Kelly A. Romano
Ms. Kelly A. Romano
Independent Chairwoman of the Board
Independent Chairwoman of the Board
80.72K
-23.06%
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
71.67K
-13.14%
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Independent Director
Independent Director
25.78K
--
James A. Johnson ,
James A. Johnson ,
Independent Director
Independent Director
5.00K
--
Ms. Barbara Kosacz, J.D.
Ms. Barbara Kosacz, J.D.
Independent Director
Independent Director
--
--
Ms. Julie Rathbun
Ms. Julie Rathbun
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
345.49K
-6.78%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
168.90K
-4.81%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
111.88K
-7.08%
Mr. Robert Renninger
Mr. Robert Renninger
Senior Vice President - Finance, Accounting
Senior Vice President - Finance, Accounting
109.19K
-2.58%
Ms. Kelly A. Romano
Ms. Kelly A. Romano
Independent Chairwoman of the Board
Independent Chairwoman of the Board
80.72K
-23.06%
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
71.67K
-13.14%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月4日 週五
更新時間: 7月4日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Perceptive Advisors LLC
13.84%
BML Capital Management LLC
8.20%
Nemean Asset Management, LLC
5.11%
The Vanguard Group, Inc.
3.94%
Propel Bio Management, LLC
3.82%
Other
65.09%
持股股東
持股股東
佔比
Perceptive Advisors LLC
13.84%
BML Capital Management LLC
8.20%
Nemean Asset Management, LLC
5.11%
The Vanguard Group, Inc.
3.94%
Propel Bio Management, LLC
3.82%
Other
65.09%
股東類型
持股股東
佔比
Investment Advisor
18.80%
Private Equity
14.16%
Corporation
5.12%
Venture Capital
3.94%
Hedge Fund
3.71%
Individual Investor
3.67%
Investment Advisor/Hedge Fund
2.40%
Research Firm
1.16%
Family Office
1.09%
Other
45.95%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
148
20.73M
53.10%
-5.78M
2025Q1
186
20.71M
53.09%
-9.10M
2024Q4
198
21.17M
54.25%
-10.35M
2024Q3
213
18.84M
48.90%
-11.53M
2024Q2
229
24.92M
64.90%
-5.72M
2024Q1
248
24.36M
63.46%
-12.25M
2023Q4
255
24.39M
64.09%
-12.11M
2023Q3
262
25.40M
66.77%
-11.45M
2023Q2
269
26.01M
68.55%
-12.86M
2023Q1
277
27.79M
73.28%
-11.27M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Perceptive Advisors LLC
5.40M
13.84%
--
--
Apr 04, 2025
BML Capital Management LLC
3.20M
8.2%
+424.78K
+15.30%
Mar 31, 2025
Nemean Asset Management, LLC
1.99M
5.11%
+1.99M
--
Apr 14, 2025
The Vanguard Group, Inc.
1.54M
3.94%
-18.74K
-1.20%
Mar 31, 2025
Propel Bio Management, LLC
1.49M
3.82%
--
--
Mar 31, 2025
Simplify Asset Management Inc
1.49M
3.82%
--
--
Mar 31, 2025
Tang Capital Management, LLC
600.00K
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
446.47K
1.14%
-1.54K
-0.34%
Mar 31, 2025
Acadian Asset Management LLC
428.53K
1.1%
-5.96K
-1.37%
Mar 31, 2025
BofA Global Research (US)
416.16K
1.07%
+15.00
+0.00%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Simplify Propel Opportunities ETF
0.67%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
iShares Neuroscience and Healthcare ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Simplify Propel Opportunities ETF
佔比0.67%
Dimensional US Core Equity 1 ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Neuroscience and Healthcare ETF
佔比0%
iShares US Small-Cap Equity Factor ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
